Participantes
DIRECCIÓN
Manuel Benito
PhD. DPhil. Complutense University & CIBERDEM (ISCIII)
Madrid, Spain
PARTICIPANTES
Jesús Ávila
Associate Professor Ad Honorem CBMSO
(CSIC-UAM)& CIBERNED (ISCIII)
Madrid,Spain
Jesús Egido
Professor and Chairman, Department of Medicine, Autonoma University
Chief, Division of Nephrology and Hypertension
Director Renal, Vascular and Diabetes Research Lab. University Hospital
Fundación Jimenez Diaz & CIBERDEM (ISCIII)
Madrid, Spain
Emily Gallagher
Assistant Professor of Medicine and Endocrinology
Division of Diabetes, Endocrinology and Bone Diseases,
Department of Medicine. Mount Sinai School of Medicine
New York, USA
Holger J. Gellermann
Dr. Medical Director
Boehringer Ingelheim Spain
CR Kahn
Chief Academic Officer, Joslin Diabetes Center
Mary K. Iacocca Professor, Harvard Medical School. Boston, U.S.A.
Anna Krook
Professor.Department of Physiology and Pharmacology
Karolinska Institute
Stockholm, Sweden
Lorenzo Pasquali
MD, PhD Germans Trias i Pujol Research Institute
Cristina Rondinone
Vicepresident R&D
Head Cardiometabolic Diseases iMED
Medimmune/Astra-Zeneca
USA
Rafael Simó Canonge
Head of Diabetes and Metabolism Research Unit
Vall d'Hebron Research Institute
Barcelona & CIBERDEM (ISCIII),
Madrid, Spain
Ulf Smith
MD, PhD. Professor of Medicine
University of Gothenburg
Sweden
Programa
Miércoles, 7 Septiembre 2016
A. Insulin resistance as the initial pathophysiological feature in type 2
15:45
Multiple Roles and Mechanisms Underlying Insulin Resistance in the Metabolic Syndrome
CR Kahn
The adipose organ: A source of insulin resistant signals
Ulf Smith
Skeletal muscle insulin sensitivity
Anna Krook
Jueves, 8 Septiembre 2016
B. Elastoplasticity of pancreatic endocrine cells: The tipe 2 diabetes progression
10:00
Molecular basis and regulatory networks of the pancreatic beta cell fate
Lorenzo Pasquali
Failure of the compensatory mechanisms of beta-cell insulin secretion: The crossroad of Autophaty/Apoptosis
Manuel Benito
12:00
Concluding remarks and Discussion
C. Type 2 diabetes and metabolic syndrome vascular complications
15:00
Type 2 diabetes, metabolic syndrome and macrovascular complications
Cristina Rondinone
Diabeteic nephropathy
Jesús Egido
Neurodegeneration in diabetic retinopathy: Therapeutic implications
Rafael Simó Canonge
18:00
Concluding remarks and Discussion
Viernes, 9 Septiembre 2016
D. Neurodegeneration and type 2 diabetes: Type 3 Diabetes?
09:00
Molecular basis of neurodegneration in the Alzheimer disease: The metabolic environment
Jesús Ávila
E. Cancer susceptibility associated to insulin resistance and type 2 diabetes
10:00
Type 2 diabetes, metabolic syndrome and cancer: The IGFI and insulin connection
Emily Gallagher
11:00
Concluding remarks and Discussion
F. Drugs Discovery: New therapeutics approaches
11:15
Beyond glucose control: addressing diabetes associated comorbidities
Holger J. Gellermann